Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluticasone + prednisone is a combination of two synthetic corticosteroids, fluticasone and prednisone. Both drugs are anti-inflammatory agents that act via the glucocorticoid receptor to suppress immune responses and reduce inflammation. Fluticasone is commonly used as an inhaled or intranasal corticosteroid for asthma, allergic rhinitis, and other inflammatory conditions of the airways or skin[3][5][8]. Prednisone is an oral systemic corticosteroid widely used for a range of inflammatory and autoimmune diseases[6]. The combination may be considered in clinical scenarios where both local (e.g., airway) and systemic anti-inflammatory effects are desired, although there is no evidence of a fixed-dose commercial product containing both agents together. Mechanistically, both drugs act as agonists at the glucocorticoid receptor to modulate gene expression, inhibit pro-inflammatory cytokines, decrease leukocyte migration, and suppress immune cell activity[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluticasone + prednisone.